Coherus Oncology, Inc. - Common Stock (CHRS)
0.6409
-0.1767 (-21.61%)
NASDAQ · Last Trade: Nov 11th, 1:42 AM EST
News & Press Releases
Coherus Oncology: 3 Key Takeaways for Long-Term Investorsfool.com
With less than 12 months of cash on hand, the margin for error is thin, and the oncologist survey on LOQTORZI's standard-of-care status may matter as much as any cost cut.
Via The Motley Fool · November 10, 2026
Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcriptfool.com
Coherus cuts 30% of staff and narrows focus to esophageal cancer as cash runway tightens.
Via The Motley Fool · November 10, 2026
What Coherus Oncology (CHRS) Said on Its Q3 Earnings Callmarketbeat.com
Coherus Oncology (NASDAQ:CHRS) plans to cut approximately 30% of its workforce and focus development of its experimental drug tagmokitug on esophageal cancer as it seeks to reduce spending and grow sales of its cancer treatment LOQTORZI.
On its third-quarter 2026 earnings call, management said the
Via MarketBeat · November 9, 2026
Coherus Oncology (NASDAQ:CHRS) Q1 Revenue Misses Estimates Despite LOQTORZI Growthchartmill.com
Via Chartmill · May 11, 2026
Coherus Oncology Inc (NASDAQ:CHRS) Reports Mixed Q4 2025 Results as LOQTORZI Sales Growchartmill.com
Via Chartmill · March 9, 2026
Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan
– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –
By Coherus Oncology, Inc. · Via GlobeNewswire · November 9, 2026
Gap-Up and Gap-Down Stocks in the Oct. 29, 2026 Sessionchartmill.com
Via Chartmill · October 29, 2026
Coherus Oncology Reports 89% Response Rate in Early ESCC Studymarketbeat.com
Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to
Via MarketBeat · October 28, 2026
Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development
-1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients-
By Coherus Oncology, Inc. · Via GlobeNewswire · October 28, 2026
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:
By Coherus Oncology, Inc. · Via GlobeNewswire · October 27, 2026
Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus Oncology, Inc. · Via GlobeNewswire · October 26, 2026
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.
By Coherus Oncology, Inc. · Via GlobeNewswire · October 14, 2026
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -
By Coherus Oncology, Inc. · Via GlobeNewswire · September 23, 2026
Coherus to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
By Coherus Oncology, Inc. · Via GlobeNewswire · August 31, 2026
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets –
By Coherus Oncology, Inc. · Via GlobeNewswire · August 17, 2026
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcriptfool.com
LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts.
Via The Motley Fool · August 12, 2026
Coherus Oncology Q2 Earnings Call Highlightsmarketbeat.com
Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise.
Chief Executive Officer Denny Lanfear said
Via MarketBeat · August 5, 2026
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $13.6 million in Q2 2026, up 15% over Q1 –
By Coherus Oncology, Inc. · Via GlobeNewswire · August 5, 2026
Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its second quarter 2026 financial results will be released on Wednesday, August 5, 2026. Starting at 5:00 p.m. Eastern Daylight Time on August 5, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus Oncology, Inc. · Via GlobeNewswire · July 22, 2026
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
By Coherus Oncology, Inc. · Via GlobeNewswire · June 23, 2026
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase
EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:ARTV),(NASDAQ:FATE),(NASDAQ:IBRX),(NASDAQ:CHRS) EQNX::TICKER_END
Via FinancialNewsMedia · May 14, 2026
Coherus Oncology Q1 Earnings Call Highlightsmarketbeat.com
Coherus Oncology (NASDAQ:CHRS) said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.
On the company’s first-quarter 2026 earnings call
Via MarketBeat · May 11, 2026
CHRS Q1 2026 Earnings Transcriptfool.com
CHRS Q1 2026 Earnings Transcript
Via The Motley Fool · May 11, 2026
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
– LOQTORZI® net revenue of $11.8 million in Q1 2026 –
By Coherus Oncology, Inc. · Via GlobeNewswire · May 11, 2026
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
By Coherus Oncology, Inc. · Via GlobeNewswire · May 4, 2026